MX2020005916A - Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido. - Google Patents
Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.Info
- Publication number
- MX2020005916A MX2020005916A MX2020005916A MX2020005916A MX2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A MX 2020005916 A MX2020005916 A MX 2020005916A
- Authority
- MX
- Mexico
- Prior art keywords
- amylin
- aqueous solution
- receptor agonist
- copolyamino acid
- injectable aqueous
- Prior art date
Links
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title abstract 4
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- 229940124035 Amylin receptor agonist Drugs 0.000 title abstract 2
- 239000007864 aqueous solution Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 150000007942 carboxylates Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a una composición en forma de una solución acuosa inyectable, para la cual el pH está comprendido de 6.0 a 8.0, que comprende al menos: a) amilina, un agonista del receptor de amilina o un análogo de amilina; b) un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos Hy, dicho copoliaminoácido está constituido por unidades glutámicas o aspárticas y dichos radicales hidrofóbicos -Hy se seleccionan de acuerdo con la fórmula X como se define a continuación: C9 (ver formula) Fórmula X caracterizada por que la composición no comprende insulina basal para la cual el punto isoeléctrico IP está comprendido de 5.8 a 8.5. También se refiere a una composición caracterizada por que también comprende una insulina prandial.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762606139P | 2017-12-07 | 2017-12-07 | |
| FR1761808A FR3074682B1 (fr) | 2017-12-07 | 2017-12-07 | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| FR1855943A FR3083085B1 (fr) | 2018-06-29 | 2018-06-29 | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| PCT/EP2018/083943 WO2019110788A1 (fr) | 2017-12-07 | 2018-12-07 | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005916A true MX2020005916A (es) | 2020-10-19 |
Family
ID=66751321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005916A MX2020005916A (es) | 2017-12-07 | 2018-12-07 | Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido. |
| MX2025008231A MX2025008231A (es) | 2017-12-07 | 2020-07-13 | Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025008231A MX2025008231A (es) | 2017-12-07 | 2020-07-13 | Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12186373B2 (es) |
| JP (1) | JP2025032188A (es) |
| KR (1) | KR20240171194A (es) |
| AU (1) | AU2024278135A1 (es) |
| IL (1) | IL275146B2 (es) |
| MX (2) | MX2020005916A (es) |
| PH (1) | PH12020550804A1 (es) |
| SA (1) | SA520412138B1 (es) |
| WO (1) | WO2019110788A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4091625A1 (en) | 2021-05-22 | 2022-11-23 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4342486A1 (en) | 2022-09-20 | 2024-03-27 | Adocia | Compositions comprising at least an insulin and an amylin receptor agonist for treating diabetes, in a patient/person having a bmi of more than 28 kg/m² and/or an hba1c of more than 7.6 % |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| IT1219712B (it) | 1988-06-14 | 1990-05-24 | Ausimont Spa | Perossiacidi eterociclici con eteroatomo "n" ammidico |
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| FR2672598A1 (fr) | 1991-02-11 | 1992-08-14 | Adir | Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| BR9407424A (pt) | 1993-09-07 | 1996-04-09 | Amylin Pharmaceuticals Inc | Métodos para regular motilidade gastrointestinal |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
| FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
| FR2843117B1 (fr) | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
| FR2855521B1 (fr) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques. |
| FR2860516B1 (fr) | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques |
| FR2873704B1 (fr) | 2004-07-30 | 2006-12-08 | Flamel Technologies Sa | Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques |
| US8084493B1 (en) | 2005-01-04 | 2011-12-27 | Gp Medical, Inc. | Pharmaceutical composition of peptide drug and enzyme-inhibition compounds |
| EP1996224B1 (en) | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| FR2910318B1 (fr) * | 2006-12-20 | 2009-07-03 | Flamel Technologies Sa | Dispersion de polyaminoacides dans une phase lipidique continue. |
| US9173991B2 (en) | 2007-07-02 | 2015-11-03 | Roche Diabetes Care, Inc. | Device for drug delivery |
| WO2009049222A1 (en) | 2007-10-12 | 2009-04-16 | Curedm, Inc. | Compositions and methods of using the human proislet peptide receptor |
| EP2078713A1 (en) | 2007-12-28 | 2009-07-15 | QuoNova GmbH | Inhibitors of biofilm formation of gram-positive and gram-negative bacteria |
| US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| TWI480070B (zh) | 2011-04-21 | 2015-04-11 | Univ Kaohsiung Medical | 具礦質親和能力之多歧狀胜肽構型 |
| BR112014010275A2 (pt) | 2011-10-31 | 2017-04-18 | Xeris Pharmaceuticals Inc | formulações para tratamento de diabetes |
| FR2985429B1 (fr) | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
| FR2985428B1 (fr) * | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
| CN113730555A (zh) * | 2012-01-09 | 2021-12-03 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
| US9347238B2 (en) | 2013-07-16 | 2016-05-24 | Eripio, Llc | Shelter lift attachment for a portable human transport system |
| CA3051737C (en) | 2014-02-03 | 2022-05-10 | Nikolaus KRALL | Low molecular weight drug conjugates for binding to carbonic anhydrase ix |
| FR3052072A1 (fr) | 2016-06-07 | 2017-12-08 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2017211918A1 (fr) | 2016-06-07 | 2017-12-14 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine |
| US10463717B2 (en) | 2016-12-27 | 2019-11-05 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid |
| CN111670042A (zh) | 2017-12-07 | 2020-09-15 | 阿道恰公司 | 包含人胰高血糖素和共聚氨基酸的可注射水溶液形式的组合物 |
| CN111727049A (zh) | 2017-12-07 | 2020-09-29 | 阿道恰公司 | Ph 7的包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的可注射溶液 |
-
2018
- 2018-12-07 KR KR1020247039933A patent/KR20240171194A/ko active Pending
- 2018-12-07 MX MX2020005916A patent/MX2020005916A/es unknown
- 2018-12-07 IL IL275146A patent/IL275146B2/en unknown
- 2018-12-07 WO PCT/EP2018/083943 patent/WO2019110788A1/fr not_active Ceased
-
2020
- 2020-06-04 PH PH12020550804A patent/PH12020550804A1/en unknown
- 2020-06-07 SA SA520412138A patent/SA520412138B1/ar unknown
- 2020-07-13 MX MX2025008231A patent/MX2025008231A/es unknown
-
2021
- 2021-08-17 US US17/404,735 patent/US12186373B2/en active Active
-
2024
- 2024-11-29 US US18/963,911 patent/US20250090638A1/en active Pending
- 2024-12-04 AU AU2024278135A patent/AU2024278135A1/en active Pending
- 2024-12-04 JP JP2024210838A patent/JP2025032188A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024278135A1 (en) | 2025-01-02 |
| US20250090638A1 (en) | 2025-03-20 |
| IL275146B2 (en) | 2025-01-01 |
| SA520412138B1 (ar) | 2023-03-16 |
| KR20240171194A (ko) | 2024-12-06 |
| IL275146B1 (en) | 2024-09-01 |
| US20210401943A1 (en) | 2021-12-30 |
| IL275146A (en) | 2020-07-30 |
| WO2019110788A1 (fr) | 2019-06-13 |
| JP2025032188A (ja) | 2025-03-11 |
| MX2025008231A (es) | 2025-08-01 |
| US12186373B2 (en) | 2025-01-07 |
| PH12020550804A1 (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019110797A8 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| MX2025008231A (es) | Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido | |
| SA518400588B1 (ar) | محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء | |
| MX2025009746A (es) | Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos | |
| SG11201810901VA (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid | |
| MY205052A (en) | Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals | |
| MX2016014944A (es) | Mejoradores de palatabilidad que comprenden reactivos amino y compuestos de carbonilo para uso en alimento para gatos. | |
| PH12020550828A1 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
| SG11202005322RA (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
| MA49678A (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale | |
| EP4585652A3 (en) | Modified lecithin for asphalt applications | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| BR112015020895A2 (pt) | composto de siloxano substancialmente linear, terminado em amina e produtos époxi feitos com o mesmo | |
| EA202091201A1 (ru) | Композиции в форме инъецируемого водного раствора, содержащие амилин, агонист рецептора амилина или аналог амилина и сополиаминокислоту | |
| BRPI0907714B8 (pt) | Dispersões agrícolas compreendendo oligômeros ou polímeros metálicos | |
| FR3061023B1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| MX2020006670A (es) | Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco. | |
| FR3074682B1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| FR3074680B1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| SG11201804902UA (en) | A composition for improving memory, learning ability, and cognitive ability | |
| MX2018012425A (es) | Composicion para estabilizacion hidrolitica de poliester. | |
| FR3074681B1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| EA202091387A1 (ru) | Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту | |
| FR3072875B1 (fr) | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| UA125589U (uk) | Композиція для естетичних ін'єкцій |